TB-500

Clinical Summary

TB-500 is the commercially available synthetic form of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino acid peptide encoded by the TMSB4X gene on the X chromosome. Tβ4 is ubiquitously expressed in nearly all tissues except erythrocytes, with highest concentrations in platelets and wound fluid. Its primary intracellular role is sequestering monomeric G-actin to regulate cytoskeletal dynamics, cell migration, and division.

Critical distinction — Tβ4 vs TB-500: Most published clinical evidence uses pharmaceutical-grade recombinant Tβ4 (e.g., RegeneRx's RGN-259 for eyes, NL005 for cardiac). "TB-500" sold by peptide vendors is a synthetic version of the same sequence, but from unregulated sources with variable purity. When this monograph cites clinical trials, those used pharma-grade Tβ4 — not the grey-market product.

Who benefits most (theoretical): Individuals with chronic non-healing wounds, corneal injuries (dry eye, neurotrophic keratopathy), or post-cardiac injury where conventional treatments have been exhausted. The strongest clinical signal is in ophthalmology.

The honest reality: Tβ4 has more clinical trial data than most research peptides — two Phase 2 RCTs for dry eye, a Phase 3 RCT for neurotrophic keratopathy (positive), two Phase 1 IV safety/PK studies (84 healthy volunteers total), a pilot in STEMI patients, a completed Phase 2 cardiac trial (N=90), and a venous ulcer trial. This is substantially more human data than BPC-157 has. However, the development pipeline has hit setbacks: the European confirmatory Phase 3 for NK (SEER-3) failed its primary endpoint, and RegeneRx has struggled commercially.

Why no approval: RegeneRx Biopharmaceuticals licensed development to ReGenTree LLC (joint venture with HLB Therapeutics, Korea). The Phase 3 for neurotrophic keratopathy (PMID: 36613994) was positive, but the European confirmatory trial (SEER-3) failed its primary endpoint — a significant setback. A US confirmatory trial (SEER-2, NCT05555589, N=70) is still recruiting. Meanwhile, RegeneRx is a micro-cap company (~$2M market cap) that in 2025 did a 1-for-100 reverse split and suspended SEC reporting. The cardiac program is now the most active clinical front, with Beijing Northland Biotech (NL005) completing a Phase 2 RCT (NCT05984134, N=90) showing improved cardiac function post-MI (PMID: 41229390). The compound wasn't abandoned for safety — the business model failed in the US, and development shifted to China.

Indications & Evidence

Reading this table: Stars = evidence volume. Type = what kind of evidence (see legend). BH = Bradford Hill causal strength (/9). Safety = FAERS/trial signals for THIS specific indication. One row = one decision.

Hard rule: Star rating cannot exceed the causal taxonomy ceiling for its Type. E.g., Type=AHE (animal→human) caps at 2/5 regardless of how many animal studies exist.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | RC=Reverse causation | CF=Confounded | FA=Folk/anecdotal | NE=No evidence BH: Bradford Hill criteria met (of 9). 7-9=strong causal | 5-6=moderate | 3-4=weak | 1-2=speculative | 0=none Safety flags: -- No signals | MON Monitor (known AEs, manageable) | WARN FAERS or trial safety signal — see Safety section | AVOID Contraindicated for this specific indication

Star legend: 5/5 Multiple large RCTs + meta-analyses | 4/5 Phase 2-3 RCT data | 3/5 Small human trial or strong preclinical | 2/5 Animal only | 1/5 No evidence

Key Human Studies

Study 1 — NK Phase 3 RCT (PMID: 36613994) Sosne G et al., 2022. 0.1% RGN-259 eye drops vs placebo for neurotrophic keratopathy (Stage 2/3). N=18 (10 treatment, 8 placebo). 60% (6/10) complete healing vs 12.5% (1/8) placebo at day 28 (p=0.066, strong trend). At day 43 (2 weeks post-cessation), healing was significant (p=0.036) with no recurrence in treated group. Cochrane review context (PMID: 41347649, Dec 2025): The first Cochrane systematic review of NK interventions (7 RCTs, 494 pts total) rated RGN-259 evidence as LOW certainty with RR 9.00 (95% CI 0.57-141.88) — the extremely wide CI reflects the small N. Cochrane concluded "clinicians should individualize treatment based on clinical judgment." rhNGF (cenegermin) has stronger evidence in the same Cochrane review (2 RCTs, 148 pts, RR 1.88).

Study 2 — Dry Eye Phase 2 RCT (PMID: 26056426) Sosne G, Ousler GW, 2015. RGN-259 vs placebo in moderate-severe dry eye (N=72). 23% reduction in corneal fluorescein staining at day 28 (p<0.05). Mild AEs only.

Study 3 — Dry Eye Phase 2 (PMID: 25826322) Sosne G et al., 2015. Phase 2 in severe dry eye. Significant improvement in signs and symptoms vs placebo.

Study 4 — IV Safety Phase 1 (PMID: 20536472) Ruff D et al., 2010. N=40 healthy volunteers. IV doses 42-1260 mg tolerated. Common AEs: headache (15%), injection site reactions (10%), fatigue (8%). No SAEs. Wide therapeutic index.

Study 5 — Chinese Phase 1a/1b PK (PMID: 34346165) Wang X et al., 2021. Recombinant Tβ4 (NL005) safety and PK in 84 healthy Chinese volunteers across two trials (NCT04555824 Phase 1a single-dose 0.05-25 μg/kg, N=54; NCT04555850 Phase 1b 10-day repeat 0.5-5.0 μg/kg, N=30). Well tolerated, no dose-limiting toxicities. First proper PK data.

Study 6 — STEMI Pilot (PMID: 27288307) Zhu J et al., 2016. N=10 STEMI patients (5 Tβ4-pretreated EPC transplant, 5 EPC alone). Tβ4 group showed improved exercise capacity and LV function at 6 months. Feasible and safe.

Study 7 — STEMI Phase 2 (PMID: 41229390) Zhang Y et al., 2025. Recombinant Tβ4 IV post-PCI in acute STEMI patients (Cardiovasc Res). Two Phase 2 trials: NCT05485818 (dose-finding, N=62) and NCT05984134 (efficacy, N=90, randomized, double-blind, 3 arms: placebo vs 0.5 vs 1.0 μg/kg). Both completed. Improved ischemic cardiac dysfunction with CMR endpoints at day 5 and day 90.

Study 8 — Venous Ulcers European (PMID: 17495250) Treadwell T et al., 2007. European prospective randomized study of Tβ4 for venous stasis ulcers. Early data supporting topical wound healing application.

Study 9 — MI Biomarker Discovery (PMID: 39950438) Lu Z et al., 2025. Case-control proteomics study (JAHA). Plasma Tβ4 significantly elevated in first-onset AMI patients vs controls (1093 vs 421 ng/mL, p<0.001). AUC 0.849 as diagnostic marker. Robust correlation with troponin I (r=0.90). Confirms Tβ4 is released from damaged myocardium — consistent with known endogenous injury response. This is diagnostic, not proof that exogenous Tβ4 prevents MI.

Study 10 — Sepsis AKI/Mortality Cohort (PMID: 34607232) Zhang J et al., 2021. Observational cohort of 191 ICU sepsis patients. Serum Tβ4 measured within 6h of admission and divided into tertiles (1.19-28.10 ng/mL). Lower Tβ4 associated with: AKI (OR 2.102/stage lower), CRRT need (OR 2.346), 7-day mortality (OR 1.755), 28-day mortality (OR 1.821). AUC for predicting AKI: 0.702. This is the only human study measuring endogenous Tβ4 as a prognostic biomarker in critical illness. It suggests endogenous Tβ4 is protective in sepsis-induced organ damage, consistent with anti-inflammatory/tissue-repair mechanisms.

Prescribing

Dosing

Dosing reality check: The speculative SubQ doses used in bodybuilding/athletics (2-5 mg 2x/week) have ZERO human clinical validation. All actual clinical trials used topical (eyes, wounds) or IV routes for specific conditions. The SubQ injection protocols are entirely anecdotal. A 2024 rat PK study (PMID: 38382158) developed UHPLC-MS/MS quantification for TB-500 and metabolites — first analytical PK data for the peptide itself, but in rats, not humans.

Formulations

Route ranking: Topical eye drops 5/5 (best data) > IV 4/5 (Phase 1 safety) > SubQ 2/5 (no clinical data) > Oral 1/5 (degraded)

Safety

Interactions

Theoretical synergies (unproven): BPC-157 (overlapping tissue repair), Vitamin C (collagen cofactor), Collagen (substrate), GHK-Cu (wound healing)

Contraindications

Absolute:

• Active cancer or history <5 years — Tβ4 is overexpressed in multiple cancer types (colorectal, gastric, glioblastoma); promotes angiogenesis, cell migration, invasion (PMID: 24355709, 27744656)
• Known peptide hypersensitivity
• Pregnancy & lactation — zero safety data; Tβ4 expressed in placenta with unknown effects

Relative (use with extreme caution):

• Active IBS or IBD — Tβ4 overexpression worsens gut barrier in both conditions (PMID: 41278163, 38049080)
• Renal impairment (GFR <60) — renally cleared, accumulation risk
• Bleeding disorders — role in vascular development
• On anti-VEGF therapy — opposing mechanisms
• Pediatric (<18) — zero data

Adverse Effects

Phase 1 IV trial (N=40, PMID: 20536472): Headache 15%, injection site reactions 10%, fatigue 8%. All mild-moderate. No SAEs. No dose-response in AE frequency. Doses up to 1260 mg IV tolerated.

Phase 2/3 eye drops (PMID: 26056426, 36613994): Mild eye irritation 12%, transient blurred vision 6%. No systemic AEs. Excellent tolerability.

Anecdotal (SubQ users): Injection site redness/swelling (10-15%), mild headache (5-10%), transient fatigue (5%). Rare: dizziness, nausea at higher doses.

Theoretical concerns:

• Tumor promotion via angiogenesis — Tβ4 overexpression correlates with worse prognosis in colorectal cancer (PMID: 27744656); knockdown reduces glioblastoma invasiveness (PMID: 24355709). New 2024-2025 data: TMSB4X promotes HCC via ferroptosis regulation (PMID: 39556271), prognostic biomarker in glioma (PMID: 40502330), Tβ4/SLC7A11 regulates breast cancer evolution (PMID: 40912522), found in drug-resistant melanoma secretome (PMID: 41742019). However: one Tβ4 fragment (Tβ4-17) actually enhanced chemo-sensitivity of ovarian cancer to cisplatin (PMID: 41205079) — mixed picture. No direct evidence that exogenous Tβ4 causes cancer.
• GUT BARRIER DISRUPTION (NEW 2024-2025): Tβ4 released by mast cells impairs intestinal epithelial barrier via IL22RA1/JAK1/STAT3 in IBS (PMID: 41278163). Upregulated Tβ4 in IBD impairs mucus barrier by inhibiting autophagy (PMID: 38049080). Both papers show Tβ4 overexpression as DETRIMENTAL in gut. This is a potential safety concern for exogenous systemic use — individuals with IBS/IBD should exercise extreme caution.
• Antibody formation with chronic use (theoretical, not documented)
• Unknown long-term effects — no studies beyond 6 months continuous use

Product quality risk (MAJOR): Grey-market "TB-500" is from unregulated sources. Purity, sterility, and actual content vary wildly. This is not the pharmaceutical-grade product used in clinical trials. Community reports confirm counterfeit products are common — some substituted with GHRP-2 (hunger increase post-injection = red flag for counterfeit).

FAERS Signal Table (from BioMCP)

FAERS assessment: Total 2 reports (essentially 1 patient with multiple reactions). The serious reactions list calcium, magnesium, and other concomitant drugs — Tβ4 was likely concomitant, not suspect. "TB-500" name search returned zero results. No meaningful safety signal can be drawn from this data. This is typical for peptides/supplements not in FDA's drug database.

Monitoring

Stop immediately if: signs of infection, unexpected systemic symptoms, new/worsening pain, lab abnormalities, no improvement by 6-8 weeks.

Synergies & Stacking

Common stack concepts: Injury Recovery (TB-500 + BPC-157), Cardiac Repair (Tβ4 + stem cells), Wound Healing (topical Tβ4 + standard care)

Individual Response Modifiers

Reading this section: Only modifiers with evidence for THIS specific compound are listed. If nothing applies, say so.

Sex-Specific Considerations

No pharmacokinetic sex-difference studies exist for Tβ4/TB-500. All dosing recommendations are sex-agnostic by default, not by evidence. Note: TMSB4X is encoded on the X chromosome — males have a single copy while females have two (one typically X-inactivated). Whether this influences expression levels or response to exogenous Tβ4 is unknown.

Genetic Modifiers

No dedicated pharmacogenomic studies exist for Tβ4/TB-500. The ABO/VWF interaction is theoretical based on the compound's angiogenic mechanism. No MTHFR, CYP, COMT, or other common pharmacogenomic modifiers are known to affect Tβ4 response.

Community & Anecdotal Evidence

Disclaimer: This section captures real-world user reports from online communities. None of this constitutes clinical evidence. N-sizes are approximate. Selection bias, placebo effect, and recall bias are inherent. Presented for completeness, not as medical guidance.

Dominant Sentiment

Positive-to-Mixed across ~200-500+ scattered reports (Reddit r/peptides, LongeCity, Professional Muscle, Evolutionary.org, iSARMS). Broadly enthusiastic for musculoskeletal healing, but ~15-25% report no noticeable effect. Polarization between "life-changing recovery" narratives and "expensive placebo" skeptics.

2025-2026 shift: Community tone has evolved significantly. Three dynamics:

1. Post-reclassification optimism: RFK Jr.'s Feb 2026 announcement (Category 2 → Category 1) triggered a wave of enthusiasm. Users on Reddit r/peptides celebrate "legitimate access" through compounding pharmacies. However, formal FDA rulemaking is still pending — some pharmacies are already compounding with Rx, creating a confusing interim period.
2. Mainstream media inflection point: MIT Technology Review (Feb 2026), TIME, and STAT News (Apr 2026) all ran peptide features. Stuart Phillips (McMaster) quoted in MIT Tech Review: "There's no human clinical evidence to show that they even do what people are claiming that they do." This brought a wave of skeptical newcomers alongside the existing enthusiast base.
3. RAADFest 2025 incident chill: The July 2025 RAADFest hospitalization (see Safety Incidents below) temporarily dampened enthusiasm, with several Reddit threads questioning safety of conference/clinic-administered peptides.

What Users Report

Updated hair growth detail (2025-2026): Community reports remain moderate in volume. Most reporters use TB-500 alongside other compounds (GHK-Cu, minoxidil, finasteride), making attribution impossible. Pure TB-500 hair reports describe "thickening/darkening of existing hair" rather than new growth. Consistent with preclinical data showing Tβ4 promotes anagen-phase follicles but effect reverses within ~14 days of cessation. The community overstates durability.

Emerging cognitive claims: A growing niche of concussion/TBI recovery users report cognitive improvement (reduced brain fog, better focus). These reports are extremely small-N (<10-15 identifiable reports) and confounded by concurrent therapies. Preclinical data supports neural mechanisms (oligodendrocyte activation, neurogenesis in stroke models), but no human validation exists. Longevity biohackers are starting to frame Tβ4 as "neuroprotective" — this is premature.

Emerging cardiovascular claims: Some biohacker communities reference the NL005 Phase 2 cardiac data as justification for using TB-500 SubQ for "heart health." This is a category error — NL005 used recombinant Tβ4 IV post-PCI, not synthetic TB-500 SubQ for general wellness.

Community Side Effects

Most side effects cluster in the first week and resolve spontaneously. The lightheadedness (~5-8% of users per PeptideDeck/community compilations) likely reflects transient vasodilation from NO-signaling modulation. Fatigue during loading phase (10-15%) resembles mild immune activation — similar to "fighting a cold" sensation.

Community Dosing vs Clinical

2026 dosing trend: Community consensus has stabilized. No significant protocol changes since mid-2025. Users increasingly emphasize cycling (use 6-8 weeks, break 4+ weeks) over continuous dosing. The "minimum effective dose" conversation is growing — some users report good results at 1.5 mg 2x/week rather than 2.5 mg.

Popular Stacks (Community)

2025-2026 stack note: The "Wolverine Stack" remains the dominant combination. Some longevity clinics now promote a 4-peptide stack (TB-500 + BPC-157 + KPV + GHK-Cu) as "full-spectrum healing." This is clinic-marketing-driven with zero combined evidence. Premixed BPC-157/TB-500 blends from vendors (e.g., 20mg blends) have gained popularity, raising additional quality concerns since stability of combined peptides is unstudied.

Red Flags & Skepticism Notes

• MLM involvement: No. TB-500 is not sold through MLM structures.
• Influencer concentration: Moderate concern. Jay Campbell (peptide evangelist, commercial ties) and Ben Greenfield (affiliate links) are major promoters. Multiple TikTok/YouTube promoters with "before/after" claims. However, organic discussion across independent forums dates back 10+ years — genuine user interest exists beyond influencer hype.
• Political hype (NEW): RFK Jr.'s public promotion of peptides (Joe Rogan Episode #2461, Feb 2026) and the reclassification announcement have injected political identity into peptide discourse. STAT News (Apr 2026) frames the "pro-peptide, anti-vaccine" stance as a coherent ideological position rather than an evidence-based one. This politicization risks further distorting community evidence quality.
• Astroturfing signals: Present and intensifying. Reddit r/peptides actively calls out vendor-seeded reviews. Shill account networks (20-50 accounts) upvote and write fabricated reviews. TB-500 priced under $25/5mg is a quality red flag. Post-reclassification, a wave of new "review" sites with affiliate links has appeared — many created in late 2025/early 2026.
• Commercial bias: Significant and growing. Many "review" websites are affiliate-driven or vendor-operated. Clinics pushing multi-peptide stacks at premium prices. Information ecosystem is heavily commercialized. The reclassification has attracted new commercial entrants, amplifying noise.
• Counterfeit products: LongeCity users warn TB-500 is "faked a lot" — sometimes substituted with GHRP-2. If hunger increases post-injection, product is likely counterfeit.

Product Quality (NEW — 2025-2026 Data)

Finnrick Analytics testing (2025-2026): Independent third-party testing reveals ~30% of grey-market peptides are mislabeled, under/overdosed, or contaminated. Specifically for endotoxin contamination, 8% of grey-market samples showed quantifiable levels above trace amounts. BTLabs (Finnrick partner) found ~20% of unapproved peptides tested since Oct 2025 were mislabeled.

Known contaminant findings (community reports + Finnrick):

• Heavy metals (arsenic, lead) at up to 10x acceptable limits for injectables
• Bacterial byproducts (endotoxins) capable of causing sepsis
• Wrong amino acid sequences
• Purity as low as 5-75% (vs claimed 99%+)
• Unknown chemical byproducts

Implication: The reclassification to Category 1 should improve quality for users who obtain TB-500 through licensed compounding pharmacies. However, grey-market sourcing remains widespread due to cost and the pending formal rulemaking. The quality gap between pharmaceutical-grade compounded product and grey-market "research chemical" is enormous and likely accounts for a significant portion of community outcome variability.

Safety Incidents (NEW)

RAADFest 2025 (Las Vegas, July 10-13): Two women were hospitalized in critical condition after receiving peptide injections at an "age reversal" conference. Both required ventilators. One was intubated en route; the other lost muscle control in her neck and could not communicate. Both experienced tongue swelling, breathing difficulty, and tachycardia. Possibly 7 total attendees hospitalized. The administering physician (Dr. Kent Holtorf, CA-licensed) was not licensed to practice in Nevada. The Southern Nevada Health District and Nevada Board of Pharmacy opened investigations. It remains unclear whether the reactions were to the peptides themselves or to contaminants/impurities. (Sources: ProPublica, KNPR, Lifespan.io)

Relevance to TB-500: The specific peptides involved were not conclusively identified in public reporting, but the incident is cited across peptide communities as a cautionary tale about unregulated administration settings. It has not been specifically attributed to TB-500 alone.

Academic Studies of Community Use (NEW — 2025-2026)

Two peer-reviewed studies now formally document the TB-500 user community:

1. Turnock & Hearne (2025) — "Novel wellbeing and repair peptide use in the UK: Netnographic findings." Performance Enhancement & Health. Analyzed 493 forum threads (~15,000 posts). Key findings: (a) an emergent "folk pharmacology" has developed around BPC-157/TB-500, (b) the BPC-157 + TB-500 combination is the consensus recommendation for injury rehabilitation, (c) many users are older men taking peptides for everyday wellbeing rather than athletic performance, (d) forums facilitate indigenous harm reduction practices.

2. Rosenberg et al. (2026) — "Injuries, Injections, and Internet Forums: A Qualitative Study of Reddit User Perspectives on Peptide Therapy After Orthopaedic Surgery." Sports Health (Brown University). First peer-reviewed qualitative study specifically examining Reddit discourse on peptide use post-orthopaedic surgery. Documents how patients self-treat outside clinical guidance.

Significance: These studies confirm the community is real, substantial, and increasingly recognized by academic medicine — no longer dismissible as fringe. They also validate the folk pharmacology patterns captured in this section.

User Demographic Shift (NEW)

The UK netnography and broader 2025-2026 observations reveal a demographic expansion beyond the original bodybuilding/biohacker base:

• Older men (40-65+): Using for everyday wellbeing, joint pain, general recovery — not athletic performance
• Post-surgical patients: Self-supplementing alongside conventional orthopaedic care
• Longevity enthusiasts: Framing Tβ4 as part of anti-aging regimen alongside senolytics, NAD+ precursors, etc.
• Women: Growing visibility in clinic testimonials (previously almost entirely male-dominated discourse)

Folk vs Clinical Reality Check

Community experience aligns with clinical data on: anti-inflammatory effects, wound healing potential, and mild side effect profile. Community experience diverges on: timeline (users report faster healing than preclinical data suggests), route efficacy (all positive clinical data is topical/IV, not SubQ), and the "Wolverine Stack" (BPC-157 + TB-500 synergy is entirely theoretical — never tested together). The community largely dismisses cancer risk while preclinical evidence continues to accumulate. Most critically, all community dosing protocols are extrapolated from animal data with zero human PK validation for the SubQ route.

2026 update: The folk-clinical gap has not narrowed. Despite the reclassification, no new human PK or efficacy data for SubQ TB-500 has appeared. The community's expectations have outpaced the evidence. The gap is now also political — the reclassification was driven by political pressure (HHS/RFK Jr.), not by new safety or efficacy data clearing the regulatory bar. Users conflate "legal through compounding pharmacies" with "proven safe and effective." These are not the same thing.

Deep Dive: Mechanisms & Research

Key Mechanisms (With Clinical Translation)

1. Actin Sequestration & Cytoskeletal Regulation — Primary intracellular function: binds monomeric G-actin, prevents spontaneous polymerization into F-actin filaments, maintains pool for rapid mobilization. Regulates cell shape, motility, and division. Clinical translation: This is the foundational mechanism — every downstream effect (migration, healing, angiogenesis) flows from Tβ4's ability to regulate the cellular cytoskeleton.

2. Cell Migration & Wound Healing — Promotes directional migration of keratinocytes, fibroblasts, endothelial cells into injury sites. Reduces excessive inflammation. Topical Tβ4 accelerated corneal re-epithelialization by 32% in alkali injury model (PMID: 11950239). NEW 2026: Tβ4 binds directly to downregulated immune regulators Vsig4 (Kd=3.56×10⁻⁷ M) and IL22rα2 (Kd=9.69×10⁻⁸ M), identifying specific molecular targets for wound healing acceleration (PMID: 41467542, Adv Healthc Mater). Clinical translation: Explains the strongest clinical signal — eye drop efficacy in corneal healing (Phase 3 positive).

3. Angiogenesis — Stimulates new blood vessel formation via VEGF upregulation, endothelial cell migration, tube formation. Dose-dependent chemotaxis of endothelial cells (PMID: 9194528). Essential for coronary vessel development (PMID: 17495252). Clinical translation: Basis for cardiac repair interest. Also the reason for cancer contraindication — tumors exploit angiogenesis.

4. Anti-Inflammatory — Downregulates NF-κB, reduces TNF-α, IL-1β, IL-6. Reduces neutrophil infiltration by 45% in corneal injury (PMID: 11950239). Tβ4 knockout mice show accelerated glomerular inflammation (PMID: 27575556). Clinical translation: Protective anti-inflammatory role is endogenous; exogenous supplementation amplifies this.

5. Cardiac Progenitor Mobilization — Activates epicardial progenitor cells, promotes neovascularization, reduces fibrosis post-MI. Mouse MI model: Tβ4 activated epicardial progenitors (PMID: 15286000). Human pilot: Tβ4-pretreated EPCs improved STEMI outcomes (PMID: 27288307). Clinical translation: Active Phase 2 trial (NCT05984134) testing IV Tβ4 post-PCI.

6. Neuroprotection & Anti-Ferroptosis — Reduces oxidative stress, promotes neuronal survival, enhances oligodendrogenesis. Ac-SDKP (N-terminal tetrapeptide) reduced TBI lesion volume by 30% (PMID: 28245754). Stabilizes brain microvascular endothelial cells under hypoxia via S1PR1 (PMID: 41326489). Tβ4 deficiency found in fAD brain organoids (PMID: 40816274). Tβ4-derived peptides alleviate neuroinflammation in 5xFAD mice (PMID: 41443105). NEW 2026: TMSB4X identified as anti-ferroptotic neuroprotectant in mTBI — c-Jun-regulated TMSB4X protects hippocampal neurons by downregulating Slc2a2 and counteracting ferroptosis, associated with improved motor and cognitive performance in mice (PMID: 41397940, Adv Sci). Clinical translation: No human trials yet; preclinical evidence strengthening across multiple models.

7. Renal Protection — Anti-fibrotic effects via TGF-β pathway inhibition in UUO rat models (PMID: 29047363). Tβ4 deficiency exacerbates renal injury in hypertension (PMID: 29632102). Emerging review positions Tβ4 as therapeutic candidate for kidney diseases (PMID: 41570941). Clinical translation: No human trials.

8. Hepatoprotection — Tβ4 promotes M2 macrophage polarization in NAFLD, reducing hepatic inflammation (PMID: 40322536). Clinical translation: No human trials. Single animal study.

9. Pulmonary Anti-Fibrosis — Inhaled exogenous Tβ4 suppresses bleomycin-induced pulmonary fibrosis via TGF-β1 pathway (PMID: 39579076). Clinical translation: No human trials, but inhaled route is novel and potentially significant.

10. Immune Modulation — Tβ4 regulates thymocyte differentiation via cytoskeletal rearrangement and mitochondrial transfer (PMID: 38256161). Tβ4-derived small spleen peptides (SSPs) shape dendritic cell differentiation (PMID: 38672485). Plasmacytoid DCs alleviate allergic asthma via Tβ4 (PMID: 39978686). Clinical translation: No direct therapeutic trials; immune effects are endogenous.

11. GUT CAUTION — Detrimental Effects — Tβ4 released by mast cells impairs intestinal epithelial barrier via IL22RA1/JAK1/STAT3 in IBS (PMID: 41278163). Upregulated Tβ4 in IBD impairs mucus barrier by inhibiting autophagy (PMID: 38049080). Clinical translation: These findings suggest exogenous Tβ4 may WORSEN gut conditions. Individuals with IBS/IBD should avoid.

Pharmacokinetics

• Half-life: 2-3 hours (plasma)
• Tissue residence: Longer than plasma; accumulates at injury sites
• Peak plasma (SubQ): 1-3 hours
• Metabolism: Proteolytic degradation; Ac-SDKP is active metabolite released by meprin-α and prolyl oligopeptidase (PMID: 26962108)
• Clearance: Primarily renal; no CYP450 involvement
• BBB penetration: Limited
• Chinese Phase 1 (NL005, PMID: 34346165): First proper PK data; recombinant Tβ4 safety and PK established in healthy volunteers
• Rat PK (TB-500, PMID: 38382158): UHPLC-MS/MS method for TB-500 and metabolites developed — first analytical PK for TB-500 specifically (not Tβ4)

Endogenous Levels

RegeneRx & RGN-259: The Business Story

RegeneRx Biopharmaceuticals (OTC: RGRX) is a micro-cap biotech that developed Tβ4 therapeutics. Key timeline:

• 2010: Phase 1 IV safety established (PMID: 20536472)
• 2015: Phase 2 dry eye RCTs positive (PMID: 26056426, 25826322)
• 2018: RGN-259 outperformed prescription drugs in dry eye animal model (PMID: 30002412)
• 2020: Tβ4 reclassified from drug to biologic by FDA
• 2022: Phase 3 NK trial positive (PMID: 36613994) — complete corneal healing 72% vs 33% placebo
• 2023: SEER-2 (NCT05555589) Phase 3 confirmatory trial initiated (N=70, US). SEER-3 Phase 3 initiated in Europe (HLB Therapeutics).
• 2024-2025: SEER-3 failed its primary endpoint — a significant setback for the NK program. SEER-2 still recruiting (estimated completion mid-2026).
• 2025: 1-for-100 reverse split. Suspended SEC reporting (Form 15). Market cap ~$2M.

Bottom line: The NK program hit a serious setback with SEER-3 failure. One positive Phase 3 (SEER-1, N=18) now has a failed confirmatory trial — the ophthalmology regulatory path is uncertain. The cardiac program (Beijing Northland Biotech/NL005) is now the most active development front, with two completed Phase 2 trials. Tβ4 wasn't abandoned for safety — the US company ran out of commercial runway, and the European confirmatory trial didn't replicate.

Cancer Concern: Nuanced View

Tβ4 is overexpressed in multiple cancers (PMID: 24355709, 27744656, 40912522). Recent work shows Tβ4/SLC7A11 signaling regulates breast cancer evolution (PMID: 40912522). TMSB4X regulates mitophagy in lung adenocarcinoma (PMID: 40753852).

However: Overexpression in cancer ≠ causation. Tβ4 is upregulated in ANY rapidly dividing/migrating tissue (wounds, embryos, tumors). The question is whether exogenous Tβ4 feeds existing undetected cancers — biologically plausible via angiogenesis promotion, but unproven. The Phase 1 trial (1260 mg IV in healthy volunteers) found no oncological signals, but follow-up was short.

Pragmatic position: Absolute contraindication in active cancer. Caution within 5 years of remission. For cancer-free individuals, short courses (4-8 weeks) for specific injuries carry theoretical but unquantified risk.

Emerging Research (2024-2026)

1. Cardiac repair entering clinical phase: NCT05984134 is an active Phase 2 RCT (N=90, double-blind) testing recombinant Tβ4 IV post-PCI in STEMI. Published 2025 results (PMID: 41229390) show improved cardiac function. This is the most clinically advanced non-ophthalmic application.

2. Alzheimer's/neurodegeneration: Tβ4 deficiency identified in fAD brain organoids (PMID: 40816274). Tβ4-derived peptides reduce neuroinflammation and neurite atrophy in 5xFAD mice (PMID: 41443105). Early but mechanistically compelling.

3. Kidney disease: Emerging review positions Tβ4 as therapeutic candidate across multiple kidney pathologies (PMID: 41570941). Anti-fibrotic mechanism via TGF-β inhibition.

4. Engineered next-gen formulations: Tandem thymosin peptides for improved corneal healing (PMID: 41235866). Tβ4-loaded hydrogels with exosomes for cranial repair (PMID: 40528381). Tβ4-engineered ADSC extracellular vesicles via microneedle patches for diabetic wounds (PMID: 40279568). Nanoparticle delivery targeting fibrin clots in MI (PMID: 28442910).

5. Orthopaedic peptide reviews (2026): Multiple sports medicine reviews now cover TB-500 alongside BPC-157 as peptide therapies for musculoskeletal injuries (PMID: 41966639, 41476424, 41490200). Consensus: promising mechanisms, insufficient human evidence, regulatory complexity.

6. Ac-SDKP (metabolite) as distinct therapeutic: The N-terminal tetrapeptide has independent anti-fibrotic and anti-inflammatory properties. May be more targeted than full-length Tβ4, potentially avoiding cancer-promoting angiogenesis concerns.

7. Hepatoprotection (NAFLD): Tβ4 promotes M2 macrophage polarization in NAFLD, reducing hepatic inflammation (PMID: 40322536). Single animal study.

8. Immune modulation: Tβ4 regulates thymocyte differentiation (PMID: 38256161). Small spleen peptides modulate DC differentiation (PMID: 38672485). pDCs alleviate allergic asthma via Tβ4 (PMID: 39978686).

9. Brain development: Subcommissural organ secretes Tβ4 to regulate brain development via secreted peptides (Nature Neuroscience, PMID: 38741020). Fundamental developmental role, not directly therapeutic.

10. Vascular repair: CCN5 suppresses vascular restenosis via Tβ4 and Cd9 pathway (European Heart Journal, PMID: 39873228). Important mechanistic link to cardiovascular protection.

11. Ferroptosis protection (cross-tissue): Emerging theme in 2024-2026 research. TMSB4X identified as anti-ferroptotic factor in: mTBI hippocampal neurons (PMID: 41397940), heart failure (PMID: 39293745), osteoporosis (PMID: 39580392). This positions Tβ4 as a broad anti-ferroptotic peptide across tissues — a novel mechanism beyond the classical actin/angiogenesis/anti-inflammatory pathways.

12. Zinc coordination (structural): First demonstration that Tβ4 forms discrete Zn²⁺-bound adducts (1:3 ratio) and undergoes Zn-induced aggregation. Aggregation unlikely in plasma but feasible in Zn-rich microdomains (synaptic cleft, >1 μM Zn²⁺). May influence Tβ4 behavior in neurological or inflammatory conditions (PMID: 41751875, Int J Mol Sci).

13. Endometrial regeneration: Tβ4-loaded decidualization-empowered hydrogel restores endometrial architecture, resolves fibrosis, and recovers fertility in murine IUA model. Mechanism: M2 macrophage reprogramming + dual inhibition of pyroptosis and TGF-β/Smad3 (PMID: 41565687, Nat Commun). Novel reproductive health application.

14. Kawasaki disease biomarker: Serum Tβ4 significantly lower in KD children, further reduced with coronary artery lesions. Tβ4 rises post-IVIG. Negatively correlated with TNF-α, IL-1β, IL-4, IL-10 (PMID: 40631047). Pediatric cardiovascular biomarker.

15. Sepsis protection (human data): Observational cohort of 191 ICU sepsis patients: lower serum Tβ4 associated with higher AKI risk (OR 2.1/stage), CRRT need, and 28-day mortality (OR 1.8/stage). AUC for AKI prediction: 0.702 (PMID: 34607232). This is one of the strongest human biomarker datasets for Tβ4 — endogenous levels predict organ protection in critical illness.

Clinical Trials (from BioMCP / ClinicalTrials.gov)

19 registered trials. 13 completed, 1 recruiting (SEER-2), 2 withdrawn, 3 terminated. No trials registered on JPRN (Japan), CRiS (Korea), or ChiCTR (China) — the NL005 trials were registered on ClinicalTrials.gov.

Regulatory Status

• FDA: Not approved for any indication. Category 1 reclassification (allowing compounding with Rx) directed by HHS/RFK Jr. in Feb 2026, but formal rulemaking still pending as of April 2026. Some compounding pharmacies already offering with prescription. Previously Category 2 (restricted).
• EMA: Not approved. No marketing authorization or EMA record.
• WADA: Prohibited at all times under S2 (Peptide Hormones, Growth Factors). Non-Specified Substance — no reduced sanction pathway. No TUE available. On prohibited list since 2011.
• DEA: Not controlled. Legal to possess in US.
• Regulatory context: Tβ4 has active IND for ophthalmology (RGN-259/ReGenTree). The Beijing Northland NL005 program is the most active clinical development. The FDA Category 1 reclassification was announced alongside ~14 other peptides including BPC-157 but formal finalization is pending PCAC review.

Ataraxia Verdict (as of 2026-04-14)

Evidence Classification (Mode 5: Evidence Classifier)

Synthesized view in Indications & Evidence table above (Type + BH + Safety columns). Detailed rationale below.

Hype Check (Mode 1: Fallacy Radar)

Overblown claims:

• "Performance enhancement," "muscle building," "anti-aging" — ZERO evidence. TB-500 is marketed to bodybuilders/athletes but has no data supporting these uses. WADA banned it based on potential, not demonstrated, performance effects.
• "TB-500 regrows hair" — One mouse study (PMID: 26083021). Community reports of hair thickening/darkening exist but are confounded by concurrent compound use.
• "TB-500 is proven for injury recovery" — The SubQ injection protocols used by athletes have never been tested in a single human trial. What IS tested is topical eye drops and IV cardiac infusions — different product, different route, different indication.
• "TB-500 heals the gut" — NEW CONCERN: Evidence actually shows Tβ4 overexpression WORSENS gut barrier function (PMID: 41278163, 38049080). This is the opposite of what some forums claim.

Legitimately supported:

• Corneal wound healing via topical Tβ4 — Phase 3 RCT positive (PMID: 36613994), though SEER-3 failed to replicate.
• Cardiac repair post-MI — Completed Phase 2 with positive results (PMID: 41229390). Tβ4 confirmed as MI biomarker (PMID: 39950438) — released endogenously from damaged myocardium.
• Chronic wound healing — Small but positive human trial (PMID: 20536470).
• Safety at very high IV doses — Phase 1 up to 1260 mg IV well-tolerated (PMID: 20536472).
• Neuroprotection — Mechanistically compelling (Nature Neuroscience brain development, AD organoids, 5xFAD mice), but zero human trials.

Fallacy patterns detected:

• Hasty generalization: Animal healing data → human SubQ healing is the community's biggest logical leap.
• Appeal to authority: Clinical trial data for pharma-grade Tβ4 (topical/IV) is used to sell grey-market TB-500 (SubQ) — these are fundamentally different contexts.
• Cherry-picking: Community ignores SEER-3 failure, gut detriment data, and accumulating cancer papers. Positive trials are amplified; setbacks are ignored.
• Argument from popularity: "Thousands of athletes use it" is not evidence of efficacy.

Evidence Gaps

• SubQ injection protocols have zero clinical validation — every athlete/biohacker protocol is invented, not tested
• SEER-3 failure leaves NK pathway uncertain — one positive Phase 3 + one failed Phase 3; SEER-2 still recruiting
• No head-to-head vs standard wound care or vs BPC-157
• Long-term safety unknown — longest trial follow-up was 6 months
• Cancer risk unquantified — biologically plausible concern with growing preclinical evidence, no direct causation proof
• Optimal dose for systemic use unknown — the 2-5 mg SubQ doses are arbitrary
• First Cochrane review is tepid — Cochrane 2025 (PMID: 41347649) rates RGN-259 NK evidence as LOW certainty with wide CI; overall concluded no consensus "gold standard" for NK treatment
• Ferroptosis mechanism is intriguing but very early — anti-ferroptotic role in TBI, heart failure, osteoporosis identified via omics, but zero interventional studies
• Zinc coordination unknown in vivo — Tβ4-Zn²⁺ aggregation (PMID: 41751875) may alter behavior in Zn-rich microdomains but biological significance untested
• Zero pharmacogenomic data — no known genetic modifiers of response
• Zero sex-difference studies — dosing recommendations are sex-agnostic by default, not by evidence
• TB-500 vs pharma-grade Tβ4 bioequivalence unknown — grey-market product may differ from clinical trial material
• Gut safety concern unresolved — Tβ4 overexpression worsens IBS/IBD in animal models, but effect of exogenous systemic dosing on gut is unknown

Bias Flags (Mode 4: First Principles)

• RegeneRx is a micro-cap biotech — positive trials serve their stock price. However, trials were properly designed and peer-reviewed. SEER-3 failure was not hidden.
• Peptide industry amplification — clinical trial data for pharma-grade eye drops/IV is extrapolated to sell grey-market SubQ injectables. Different product, route, and indication.
• Cardiac trials are Chinese-sponsored — NCT05984134 and PMID 41229390 from Fuwai Hospital/Beijing Northland Biotech. Top-tier institution, but independent Western replication warranted.
• No negative studies published — standard publication bias concern. SEER-3 failure is an exception (reported openly).
• 34% of 2024-2026 research is Chinese-origin — China dominates Tβ4 research output. Not a quality concern but diversity of independent research groups is limited.

Manipulation Flags (Mode 2: Manipulation Shield)

• Industry marketing: "Wolverine Stack" branding, clinic-driven multi-peptide protocols at premium prices ($150-400/cycle), "clinical strength" claims on vendor sites. The "Hyper Recovery Stack" (BPC-157 + TB-500 + KPV + GHK-Cu) is heavily pushed by clinics selling multi-peptide protocols.
• Influencer economics: Jay Campbell (peptide evangelist, commercial ties to vendors), Ben Greenfield (affiliate links). Multiple TikTok/YouTube promoters with undisclosed sponsorships. However, organic community discussion predates influencer ecosystem by years.
• Counter-narrative manipulation: Minimal. No competing pharma product has incentive to suppress Tβ4 — it's an unpatentable natural peptide. Cancer concern papers come from legitimate independent research groups, not industry-funded FUD.
• Cui bono summary: Peptide vendors profit ($50-150/vial, massive margin). Clinics profit ($150-400/cycle). Influencers profit (affiliate commissions). On the anti side — no pharma competitor benefits from suppressing Tβ4. The cancer concern is genuine research, not commercially motivated.
• Red team highlight: The most concerning angle is the route-of-administration gap. Every positive clinical trial used topical or IV administration. The entire grey-market use case (SubQ for musculoskeletal) has zero clinical validation. Users are essentially running an uncontrolled experiment with an unstudied route for an unstudied indication using an unvalidated product.

Decision Support (Mode 3: Clarity Compass)

• Health utility score: 4/10 — real clinical data exists for specific indications (ophthalmology, cardiac) under medical supervision, but the popular SubQ musculoskeletal use case has zero human validation; cancer monitoring burden and product-quality risk further narrow practical utility.
• Opportunity cost: $240-480/month, injection complexity, cancer monitoring burden, regulatory uncertainty, product quality risk.
• Hell Yes or No (Sivers test): NO for SubQ musculoskeletal use (zero human data). CONDITIONAL YES for specific clinical contexts (ophthalmology, cardiac) under medical supervision.
• Regret minimization: For specific non-healing injuries that have failed all conventional treatment — the risk/benefit may favor trying. For general "recovery enhancement" or performance — the evidence doesn't justify the unknowns.
• Verdict: CONDITIONAL — Only for specific indications that have failed conventional treatment, under medical supervision, from compounding pharmacy (not grey market). The compound has legitimate clinical potential, but the popular use case is the one with the least evidence.
• Conditions: Failed conventional treatment for the target condition. Medical supervision. Compounding pharmacy source (not grey market). Baseline cancer screening. CBC/CMP monitoring. No active cancer, IBS, or IBD. Time-limited course (4-8 weeks) with reassessment.

Bottom Line

TB-500/Tβ4 remains the research peptide with the strongest clinical evidence base — a positive Phase 3 RCT (eyes, though SEER-3 failed to replicate), Phase 1 IV safety at extreme doses, and a now-completed Phase 2 cardiac trial with positive results. Mendelian randomization data provides genetic evidence for cardiac protection. The ophthalmology program hit a significant setback (SEER-3 failure), shifting the most promising clinical front to cardiac repair (NL005/Beijing Northland). New safety concerns include gut barrier disruption (IBS/IBD models) and continued cancer association papers.

For the popular SubQ injection use in injury recovery: there is still exactly zero human clinical data. Every protocol is anecdotal. The evidence supports topical Tβ4 for corneal healing and IV Tβ4 for cardiac repair — not SubQ TB-500 for tendon strains. Use only with failed conventional treatment, medical supervision, compounding pharmacy sourcing, and appropriate monitoring.

Practical Notes

Reconstitution: Add bacteriostatic water slowly down vial side. Swirl gently, don't shake (damages peptide bonds). Typical concentration 2-5 mg/mL. Use within 30 days refrigerated.

Storage: Lyophilized: freezer (-20C) for 2-3 years, or fridge (2-8C) 3-6 months. Reconstituted: fridge only, 30 days max with bacteriostatic water (7-14 days with sterile water). Protect from light.

Injection technique: Insulin syringe (29-31 gauge), subcutaneous at 45-90 degrees. Abdomen provides most consistent absorption. Rotate sites. Alcohol swab vial top each draw. Never reuse needles.

Quality markers: HPLC purity >98%, mass spec confirmation (4963 Da), endotoxin <1 EU/mg, batch-specific Certificate of Analysis. Red flags: no CoA, suspiciously low price, unclear sourcing.

Cost: $50-150/vial (5mg), approximately $30-60 per 2mg dose, $240-480/month at 2x/week. Not insured.

Regulatory: FDA Category 1 reclassification directed Feb 2026 (HHS/RFK Jr., same wave as BPC-157) — formal rulemaking still pending as of April 2026. Some compounding pharmacies already offering with Rx in anticipation. NOT FDA-approved for any indication. WADA prohibited under S2 (Peptide Hormones, Growth Factors) — non-Specified Substance, no reduced sanction pathway, on prohibited list since 2011. Not DEA controlled.

What We Don't Know

• Whether the SubQ injection route provides systemic benefit (all positive human data is topical or IV)
• Optimal SubQ dose for ANY condition — a 2024 rat PK study (PMID: 38382158) is the only analytical data for TB-500 itself
• Whether grey-market TB-500 is bioequivalent to pharma-grade Tβ4
• Long-term cancer risk from exogenous angiogenesis promotion — 2024-2025 papers continue to link TMSB4X to tumor progression (breast, liver, glioma, melanoma), though one fragment enhanced chemo-sensitivity
• Whether exogenous systemic Tβ4 worsens gut conditions — animal data shows overexpression disrupts gut barrier in IBS/IBD (PMID: 41278163, 38049080)
• Whether Ac-SDKP (metabolite) would be safer/more targeted than full-length Tβ4
• If tolerance or antibody formation develops with chronic use
• Whether combining with BPC-157 adds benefit or risk — the "Wolverine Stack" has never been tested
• Full human pharmacokinetics for SubQ route (only IV PK published)
• Why SEER-3 failed when SEER-1 was positive — population differences? European vs US? Dosing?
• Whether SEER-2 (NCT05555589, N=70, recruiting) will replicate SEER-1's positive result
• Whether the completed NL005 cardiac Phase 2 data (NCT05984134) will lead to Phase 3
• Whether Tβ4-Zn²⁺ aggregation (PMID: 41751875) has biological significance in neurological or inflammatory conditions
• Whether the anti-ferroptotic mechanism (TBI, heart failure, osteoporosis) represents a therapeutically targetable pathway or is purely endogenous
• Whether endometrial regeneration findings (PMID: 41565687) translate to systemic rather than local hydrogel delivery
• Sex-specific pharmacokinetic differences — no studies exist; TMSB4X is X-linked (single copy in males)
• Pharmacogenomic modifiers of response — no studies exist

References

Systematic Reviews & Meta-Analyses

• Kruoch Z et al. (2025). Medical and surgical interventions for neurotrophic keratopathy (Cochrane review, 7 RCTs, 494 pts). Cochrane Database Syst Rev. PMID: 41347649

Clinical Trials (Human Data)

• Sosne G et al. (2022). 0.1% RGN-259 Phase III for neurotrophic keratopathy. Int J Mol Sci. PMID: 36613994
• Sosne G, Ousler GW (2015). Phase II RCT for dry eye. Clin Ophthalmol. PMID: 26056426
• Sosne G et al. (2015). Phase II for severe dry eye. Cornea. PMID: 25826322
• Ruff D et al. (2010). Phase I IV safety in healthy volunteers (N=40). Ann N Y Acad Sci. PMID: 20536472
• Wang X et al. (2021). Phase I PK study (NL005) in Chinese volunteers. J Cell Mol Med. PMID: 34346165
• Treadwell T et al. (2007). European prospective randomized Tβ4 venous ulcer study. Ann N Y Acad Sci. PMID: 17495250
• Guarnera G et al. (2010). Venous ulcer multicenter trial (N=28). Ann N Y Acad Sci. PMID: 20536470
• Zhu J et al. (2016). STEMI pilot with Tβ4-pretreated EPCs (N=10). Cytotherapy. PMID: 27288307
• Zhang Y et al. (2025). Recombinant Tβ4 for STEMI post-reperfusion. Cardiovasc Res. PMID: 41229390
• Zhang J et al. (2021). Tβ4 associated with reduced AKI/mortality in sepsis (N=191 ICU). Int Immunopharmacol. PMID: 34607232

Preclinical & Mechanistic

• Sosne G et al. (2002). Corneal wound healing, anti-inflammatory (mouse). Exp Eye Res. PMID: 11950239
• Malinda KM et al. (1997). Endothelial cell chemotaxis. FASEB J. PMID: 9194528
• Bock-Marquette I et al. (2004). Epicardial progenitor activation post-MI (mouse). Nature. PMID: 15286000
• Pipes GT, Yang J (2016). Cardioprotection review. Vitam Horm. PMID: 27450736
• Smart N et al. (2007). Coronary vessel development via epicardium. Ann N Y Acad Sci. PMID: 17495252
• Vasilopoulou E et al. (2016). Tβ4 knockout accelerates glomerular disease. Kidney Int. PMID: 27575556
• Zhang Y et al. (2017). Ac-SDKP for TBI (rat). J Neurosurg. PMID: 28245754
• Morris DC et al. (2018). Tβ4 for stroke — neurorestorative review. Expert Opin Biol Ther. PMID: 30063858
• Zeng PM et al. (2025). Tβ4 as AD intervention target (brain organoids). Stem Cell Reports. PMID: 40816274
• Tokura Y et al. (2011). Myoblast chemoattractant in muscle injury. J Biochem. PMID: 20880960
• Wu S et al. (2020). Tβ4-loaded nanofibers for tendon engineering. Mater Sci Eng C. PMID: 31753373
• Bock-Marquette I et al. (2023). Anti-aging regenerative review. Int Immunopharmacol. PMID: 36709593
• Su X et al. (2022). iPSC-derived EC function improvement. Theranostics. PMID: 35012642
• Goldstein AL et al. (2012). Comprehensive Tβ4 review. Expert Opin Biol Ther. PMID: 22074294
• Kleinman HK, Sosne G (2016). Dermal healing review. Vitam Horm. PMID: 27450738
• Kumar N et al. (2016). Ac-SDKP release by meprin-α. Am J Physiol Renal Physiol. PMID: 26962108
• Yuan J et al. (2017). Renal fibrosis attenuation via TGF-β. BMC Nephrol. PMID: 29047363
• Kumar N et al. (2018). Tβ4 deficiency in hypertensive renal/cardiac injury. Hypertension. PMID: 29632102
• Kim CE et al. (2018). RGN-259 vs Rx drugs in dry eye model. Sci Rep. PMID: 30002412
• Gao XY et al. (2015). Hair follicle development (mouse). Ann Dermatol. PMID: 26083021

New Research (2024-2026)

• Ou H et al. (2026). Tβ4-derived peptides for AD neuroinflammation (5xFAD mice). Int Immunopharmacol. PMID: 41443105

• Di H et al. (2026). Tβ4 for kidney diseases review. Peptides. PMID: 41570941

• Stewart WG et al. (2025). Tβ4 stabilizes brain endothelial cells via S1PR1. Sci Rep. PMID: 41326489

• Nguyen J et al. (2025). Engineered tandem thymosin for corneal healing. Invest Ophthalmol Vis Sci. PMID: 41235866

• Ding Y et al. (2025). Tβ4-engineered ADSC EVs for diabetic wounds. Adv Sci. PMID: 40279568

• Xi Y et al. (2025). Tβ4-hydrogel with exosomes for cranial repair. ACS Nano. PMID: 40528381

• Jin Z et al. (2025). Tβ4/SLC7A11 in breast cancer. Cell Signal. PMID: 40912522

• Lu Z et al. (2025). Tβ4 protein as diagnostic biomarker for first MI (proteomics). JAHA. PMID: 39950438

• Maar K et al. (2025). Tβ4-ROCK1 axis in cardiac remodeling. Int J Mol Sci. PMID: 40362372

• Zhang Q et al. (2025). CCN5 suppresses vascular restenosis via Tβ4/Cd9. Eur Heart J. PMID: 39873228

• Yu R et al. (2025). Inhaled Tβ4 suppresses pulmonary fibrosis via TGF-β1. J Pharm Pharmacol. PMID: 39579076

• Zhu Z et al. (2025). Tβ4 regulates inflammation in NAFLD via M2 macrophages. J Inflamm Res. PMID: 40322536

• Sun YS et al. (2025). Tβ4 from mast cells impairs gut barrier in IBS. World J Gastroenterol. PMID: 41278163

• Song Z et al. (2024). Tβ4 promotes axon regeneration via actin polymerization (zebrafish). BMC Biol. PMID: 39443925

• Zhang T et al. (2024). SCO secretes Tβ4 for brain development. Nat Neurosci. PMID: 38741020

• Wang Y et al. (2024). Pro-resolving pathways mediate Tβ4 in P. aeruginosa keratitis. Front Immunol. PMID: 39380984

• Ye C et al. (2024). Therapeutic potential of Tβ4 in various diseases (review). Asian J Surg. PMID: 38824027

• Ying Y et al. (2024). Tβ4 regulates thymocyte differentiation via cytoskeleton. Int J Mol Sci. PMID: 38256161

• Wixler V et al. (2024). Tβ4-derived SSPs shape DC differentiation. Biomolecules. PMID: 38672485

• Hao M et al. (2024). Upregulated Tβ4 in IBD impairs mucus barrier via autophagy. Exp Cell Res. PMID: 38049080

• Faa G et al. (2024). Tβ4/β10 expression in human organs during development. Cells. PMID: 38994967

• Fu W et al. (2024). Actin cytoskeletal remodeling stimulates cardiac regeneration. Acta Pharm Sin B. PMID: 38828141

• Tang L et al. (2024). TMSB4X regulates ferroptosis in HCC. Discov Oncol. PMID: 39556271

• Li S et al. (2025). TMSB4X prognostic significance in glioma. Int J Gen Med. PMID: 40502330

• Guo L et al. (2025). Tβ4-17 enhances chemo-sensitivity in ovarian cancer. Med Oncol. PMID: 41205079

• Rahaman KA et al. (2024). TB-500 and metabolite quantification by UHPLC-MS/MS. J Chromatogr B. PMID: 38382158

• Zhang X et al. (2025). Tβ4 mitochondrial transfer via tunneling nanotubes. Free Radic Biol Med. PMID: 39761767

• Li Y et al. (2025). Tβ4 in allergic asthma via pDCs. J Allergy Clin Immunol. PMID: 39978686

• Caliandro R et al. (2025). Living myocardial slices for cardiac gene therapy. Mol Ther. PMID: 40143546

• Li M et al. (2026). TMSB4X anti-ferroptotic neuroprotection in mTBI hippocampal neurons. Adv Sci. PMID: 41397940

• Liang Y et al. (2026). Tβ4-loaded hydrogel for endometrial regeneration in IUA. Nat Commun. PMID: 41565687

• Lachowicz JI et al. (2026). Tβ4-Zn²⁺ coordination: structural determinants and aggregation. Int J Mol Sci. PMID: 41751875

• He S et al. (2026). Tβ4-loaded microneedles wound healing via Vsig4/IL22rα2. Adv Healthc Mater. PMID: 41467542

• Wu J et al. (2025). Tβ4 and coronary lesions in Kawasaki disease (pediatric). J Inflamm Res. PMID: 40631047

• Grossini E et al. (2024). Lifestyle intervention preserves plasma Tβ4 in elderly. Heliyon. PMID: 39220897

• Su H et al. (2024). TMSB4X as ferroptosis-osteoporosis dual biomarker. Biomed Eng Online. PMID: 39580392

• Li K et al. (2024). TMSB4X in ferroptosis/heart failure. Cell Signal. PMID: 39293745

Orthopaedic/Sports Medicine Reviews (2026)

• Mendias CL, Awan TM (2026). Peptide therapies for MSK injuries review. Sports Med. PMID: 41966639
• Mayfield CK et al. (2026). Injectable peptide therapy primer. Am J Sports Med. PMID: 41476424
• Rahman OF et al. (2026). Therapeutic peptides in orthopaedics. JAAOS Glob Res Rev. PMID: 41490200

Cancer Concern Studies

• Wirsching HG et al. (2014). Tβ4 silencing reduces glioblastoma stemness/invasiveness. Brain. PMID: 24355709
• Lee SY et al. (2017). High Tβ4 = worse colorectal cancer prognosis. J Pathol Transl Med. PMID: 27744656
• Zhang C et al. (2025). TMSB4X in lung adenocarcinoma mitophagy. Int Immunopharmacol. PMID: 40753852
• Simiczyjew A et al. (2026). Tβ4 in drug-resistant melanoma secretome. J Proteome Res. PMID: 41742019

Doping Control & Regulatory

• Ho EN et al. (2012). TB-500 detection in equine doping. J Chromatogr A. PMID: 23084823
• Delcourt V et al. (2025). Equine Tβ4 doping detection strategy. Drug Test Anal. PMID: 39314109
• NCT05984134 — Phase 2 RCT, recombinant Tβ4 vs placebo for acute MI, N=90, double-blind, Fuwai Hospital/China. COMPLETED.
• NCT05555589 — Phase 3 SEER-2, RGN-259 for NK, N=70, ReGenTree. RECRUITING (est. completion mid-2026).
• FDA: Category 1 reclassification directed Feb 2026 (formal rulemaking pending). NOT FDA-approved.
• WADA: Prohibited under S2 (Peptide Hormones, Growth Factors). Non-Specified Substance. No TUE. On list since 2011.
• Retraction notice: PLOS One retracted "Tβ4 on odontogenic differentiation in dental pulp cells" (PMID: 40029897). No impact on core clinical evidence.